Microstructured dextran hydrogels for burst-free sustained release of PEGylated protein drugs

Biomaterials

Volumn 63, Issue , 2015, Pages 146-157

  Bae, Ki Hyun ^a   Lee, Fan ^a   Xu, Keming ^a   Keng, Choong Tat ^b   Tan, Sue Yee ^b   Tan, Yee Joo ^b,c   Chen, Qingfeng ^b,c,d   Kurisawa, Motoichi ^a  

^a INSTITUTE OF BIOENGINEERING AND NANOTECHNOLOGY   (Singapore)

^b INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d SINGAPORE MIT ALLIANCE FOR RESEARCH AND TECHNOLOGY   (Singapore)

Author keywords

Controlled drug release; Dextran; Hydrogels; Microstructure; Protein

Indexed keywords

ANTIBIOTICS; DEXTRAN; DRUG PRODUCTS; GLYCOPROTEINS; HYDROGELS; MEDICAL APPLICATIONS; MICROSTRUCTURE;

BIOMEDICAL APPLICATIONS; CIRCULATION HALF-LIFES; CONTROLLED DRUG RELEASE; EFFECTIVE APPROACHES; ENCAPSULATED PROTEINS; PEGYLATED PROTEINS; PROTEIN DELIVERY SYSTEMS; PROTEIN RELEASE KINETICS;

PROTEINS;

DEXTRAN; PEGINTERFERON ALPHA2A; ALPHA INTERFERON; ANTIVIRUS AGENT; DELAYED RELEASE FORMULATION; HYDROGEL; MACROGOL DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DRUG ACTIVITY; DRUG HALF LIFE; HEPATITIS C; HUMAN; HUMAN CELL; HYDROGEL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; MOUSE MODEL; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; SUSTAINED DRUG RELEASE; ANIMAL; CHEMISTRY; DELAYED RELEASE FORMULATION; DRUG EFFECTS; HEPACIVIRUS; ISOLATION AND PURIFICATION; LIVER; MALE; PATHOLOGY; TUMOR CELL LINE; VIROLOGY;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE, TUMOR; DELAYED-ACTION PREPARATIONS; DEXTRANS; HEPACIVIRUS; HEPATITIS C; HUMANS; HYDROGELS; INTERFERON-ALPHA; LIVER; MALE; MICE; POLYETHYLENE GLYCOLS;

EID: 84940390641     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2015.06.008     Document Type: Article

References (53)

1. Harris J.M., Chess R.B. Effect of pegylation on pharmaceuticals. Nat. Rev. Drug Discov. 2003, 2:214-221.
2. Ravaud A., Bedane C., Geoffrois L., Lesimple T., Delaunay M. Toxicity and feasibility of adjuvant high-dose interferon alpha-2b in patients with melanoma in clinical oncologic practice. Br. J. Cancer 1999, 80:1767-1769.
3. Tsutsumi Y., Onda M., Nagata S., Lee B., Kreitman R.J., Pastan I. Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:8548-8553.
4. Knop K., Hoogenboom R., Fischer D., Schubert U.S. Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angew. Chem. Int. Ed. Engl. 2010, 49:6288-6308.
5. Heathcote E.J., Shiffman M.L., Cooksley W.G., Dusheiko G.M., Lee S.S., Balart L., et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N. Engl. J. Med. 2000, 343:1673-1680.
6. Heim M.H. 25 years of interferon-based treatment of chronic hepatitis C: an epoch coming to an end. Nat. Rev. Immunol. 2013, 13:535-542.
7. Peppas N.A., Bures P., Leobandung W., Ichikawa H. Hydrogels in pharmaceutical formulations. Eur. J. Pharm. Biopharm. 2000, 50:27-46.
8. Sakaguchi K., Shimizu T., Horaguchi S., Sekine H., Yamato M., Umezu M., et al. In vitro engineering of vascularized tissue surrogates. Sci. Rep. 2013, 3:1316.
9. Sun G., Zhang X., Shen Y.I., Sebastian R., Dickinson L.E., Fox-Talbot K., et al. Dextran hydrogel scaffolds enhance angiogenic responses and promote complete skin regeneration during burn wound healing. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:20976-20981.
10. Yonet-Tanyeri N., Rich M.H., Lee M., Lai M.H., Jeong J.H., DeVolder R.J., et al. The spatiotemporal control of erosion and molecular release from micropatterned poly(ethylene glycol)-based hydrogel. Biomaterials 2013, 34:8416-8423.
11. Nguyen M.K., Jeon O., Krebs M.D., Schapira D., Alsberg E. Sustained localized presentation of RNA interfering molecules from in situ forming hydrogels to guide stem cell osteogenic differentiation. Biomaterials 2014, 35:6278-6286.
12. Chaturvedi K., Ganguly K., Nadagouda M.N., Aminabhavi T.M. Polymeric hydrogels for oral insulin delivery. J. Control Release 2013, 165:129-138.
13. Peppas N.A., Hilt J.Z., Khademhosseini A., Langer R. Hydrogels in biology and medicine: from molecular principles to bionanotechnology. Adv. Mater. 2006, 18:1345-1360.
14. Vermonden T., Censi R., Hennink W.E. Hydrogels for protein delivery. Chem. Rev. 2012, 112:2853-2888.
15. Ganguly K., Chaturvedi K., More U.A., Nadagouda M.N., Aminabhavi T.M. Polysaccharide-based micro/nanohydrogels for delivering macromolecular therapeutics. J. Control Release 2014, 193:162-173.
16. Patil N.S., Dordick J.S., Rethwisch D.G. Macroporous poly(sucrose acrylate) hydrogel for controlled release of macromolecules. Biomaterials 1996, 17:2343-2350.
17. Kim S., Kim J.H., Jeon O., Kwon I.C., Park K. Engineered polymers for advanced drug delivery. Eur. J. Pharm. Biopharm. 2009, 71:420-430.
18. Cadée J.A., de Groot C.J., Jiskoot W., den Otter W., Hennink W.E. Release of recombinant human interleukin-2 from dextran-based hydrogels. J. Control Release 2002, 78:1-13.
19. van de Wetering P., Metters A.T., Schoenmakers R.G., Hubbell J.A. Poly(ethylene glycol) hydrogels formed by conjugate addition with controllable swelling, degradation, and release of pharmaceutically active proteins. J. Control Release 2005, 102:619-627.
20. Lee F., Chung J.E., Kurisawa M. An injectable hyaluronic acid-tyramine hydrogel system for protein delivery. J. Control Release 2009, 134:186-193.
21. Meyvis T., De Smedt S., Stubbe B., Hennink W., Demeester J. On the release of proteins from degrading dextran methacrylate hydrogels and the correlation with the rheologic properties of the hydrogels. Pharm. Res. 2001, 18:1593-1599.
22. Verheyen E., Delain-Bioton L., van der Wal S., el Morabit N., Barendregt A., Hennink W.E., et al. Conjugation of methacrylamide groups to a model protein via a reducible linker for immobilization and subsequent triggered release from hydrogels. Macromol. Biosci. 2010, 10:1517-1526.
23. Griffin D.R., Schlosser J.L., Lam S.F., Nguyen T.H., Maynard H.D., Kasko A.M. Synthesis of photodegradable macromers for conjugation and release of bioactive molecules. Biomacromolecules 2013, 14:1199-1207.
24. Leach J.B., Schmidt C.E. Characterization of protein release from photocrosslinkable hyaluronic acid-polyethylene glycol hydrogel tissue engineering scaffolds. Biomaterials 2005, 26:125-135.
25. Stanwick J.C., Baumann M.D., Shoichet M.S. Enhanced neurotrophin-3 bioactivity and release from a nanoparticle-loaded composite hydrogel. J. Control Release 2012, 160:666-675.
26. Lin C.C., Anseth K.S. PEG hydrogels for the controlled release of biomolecules in regenerative medicine. Pharm. Res. 2009, 26:631-643.
27. Mundargi R.C., Babu V.R., Rangaswamy V., Patel P., Aminabhavi T.M. Nano/micro technologies for delivering macromolecular therapeutics using poly(D,L-lactide-co-glycolide) and its derivatives. J. Control Release 2008, 125:193-209.
28. Albertsson P.-Å. Partition of cell particles and macromolecules in polymer two-phase systems. Adv. Protein Chem. 1970, 24:309-341.
29. Moriyama K., Ooya T., Yui N. Hyaluronic acid grafted with poly(ethylene glycol) as a novel peptide formulation. J. Control Release 1999, 59:77-86.
30. Jin R., Hiemstra C., Zhong Z., Feijen J. Enzyme-mediated fast in situ formation of hydrogels from dextran-tyramine conjugates. Biomaterials 2007, 28:2791-2800.
31. Leach J.B., Bivens K.A., Patrick C.W., Schmidt C.E. Photocrosslinked hyaluronic acid hydrogels: natural, biodegradable tissue engineering scaffolds. Biotechnol. Bioeng. 2003, 82:578-589.
32. Lin C.C., Metters A.T. Hydrogels in controlled release formulations: network design and mathematical modeling. Adv. Drug Deliv. Rev. 2006, 58:1379-1408.
33. Hayashi Y., Milton Harris J., Hoffman A.S. Delivery of PEGylated drugs from mucoadhesive formulations by pH-induced disruption of H-bonded complexes of PEG-drug with poly(acrylic acid). React. Funct. Polym. 2007, 67:1330-1337.
34. Vrolijk J.M., Kaul A., Hansen B.E., Lohmann V., Haagmans B.L., Schalm S.W., et al. A replicon-based bioassay for the measurement of interferons in patients with chronic hepatitis C. J. Virol. Methods 2003, 110:201-209.
35. Xu K., Lee F., Gao S.J., Chung J.E., Yano H., Kurisawa M. Injectable hyaluronic acid-tyramine hydrogels incorporating interferon-alpha2a for liver cancer therapy. J. Control Release 2013, 166:203-210.
36. Kajjari P.B., Manjeshwar L.S., Aminabhavi T.M. Novel blend microspheres of cellulose triacetate and bee wax for the controlled release of nateglinide. J. Ind. Eng. Chem. 2014, 20:397-404.
37. Chen Q., Khoury M., Limmon G., Choolani M., Chan J.K., Chen J. Human fetal hepatic progenitor cells are distinct from, but closely related to, hematopoietic stem/progenitor cells. Stem Cells 2013, 31:1160-1169.
38. Zhang Y., Huo M., Zhou J., Xie S. PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in microsoft excel. Comput Methods Programs Biomed. 2010, 99:306-314.
39. Keng C.T., Sze C.W., Zheng D.H., Zheng Z.Q., Yong K., Tan S.Q., et al. Characterization of liver pathogenesis, human immune responses and drug testing in a humanized mouse model of hepatitis C virus infection. Gut 2015, (in press).
40. Mehvar R. Dextrans for targeted and sustained delivery of therapeutic and imaging agents. J. Control Release 2000, 69:1-25.
41. Kurisawa M., Chung J.E., Yang Y.Y., Gao S.J., Uyama H. Injectable biodegradable hydrogels composed of hyaluronic acid-tyramine conjugates for drug delivery and tissue engineering. Chem. Commun. (Camb) 2005, 4312-4314.
42. Teixeira L.S., Feijen J., van Blitterswijk C.A., Dijkstra P.J., Karperien M. Enzyme-catalyzed crosslinkable hydrogels: emerging strategies for tissue engineering. Biomaterials 2012, 33:1281-1290.
43. Elbert D.L. Liquid-liquid two-phase systems for the production of porous hydrogels and hydrogel microspheres for biomedical applications: A tutorial review. Acta Biomater. 2011, 7:31-56.
44. Moriyama K., Yui N. Regulated insulin release from biodegradable dextran hydrogels containing poly(ethylene glycol). J. Control Release 1996, 42:237-248.
45. Wang L.S., Du C., Chung J.E., Kurisawa M. Enzymatically cross-linked gelatin-phenol hydrogels with a broader stiffness range for osteogenic differentiation of human mesenchymal stem cells. Acta Biomater. 2012, 8:1826-1837.
46. Lee S.H., Lee Y., Chun Y.W., Crowder S.W., Young P.P., Park K.D., et al. In situ crosslinkable gelatin hydrogels for vasculogenic induction and delivery of mesenchymal stem cells. Adv. Funct. Mater. 2014, 24:6771-6781.
47. Long M.S., Jones C.D., Helfrich M.R., Mangeney-Slavin L.K., Keating C.D. Dynamic microcompartmentation in synthetic cells. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:5920-5925.
48. Grace M.J., Lee S., Bradshaw S., Chapman J., Spond J., Cox S., et al. Site of pegylation and polyethylene glycol molecule size attenuate interferon-alpha antiviral and antiproliferative activities through the JAK/STAT signaling pathway. J. Biol. Chem. 2005, 280:6327-6336.
49. Shultz L.D., Ishikawa F., Greiner D.L. Humanized mice in translational biomedical research. Nat. Rev. Immunol. 2007, 7:118-130.
50. Drake A.C., Chen Q., Chen J. Engineering humanized mice for improved hematopoietic reconstitution. Cell. Mol. Immunol. 2012, 9:215-224.
51. Lynn A.D., Blakney A.K., Kyriakides T.R., Bryant S.J. Temporal progression of the host response to implanted poly(ethylene glycol)-based hydrogels. J. Biomed. Mater. Res. A 2011, 96:621-631.
52. Cadée J.A., Luyn M.J.V., Brouwer L.A., Plantinga J.A., Wachem P.B.V., Groot C.J.D., et al. In vivo biocompatibility of dextran-based hydrogels. J. Biomed. Mater. Res. 2000, 50:397-404.
53. Judge A.D., Bola G., Lee A.C., MacLachlan I. Design of noninflammatory synthetic siRNA mediating potent gene silencing in vivo. Mol. Ther. 2006, 13:494-505.